Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
ZNF191 alters DNA methylation and activates the PI3K-AKT pathway in hepatoma cells via transcriptional regulation of DNMT1
Yufeng Liu et al.
CANCER MEDICINE (2022)
Inhibition of human lung cancer cells by anti-p21Ras scFv mediated by the activatable cell-penetrating peptide
Yu Du et al.
ANTI-CANCER DRUGS (2022)
Treatment outcomes and prognosis of patients with primary and acquired BRAF-mutated non-small cell lung cancer: A multicenter retrospective study
Wenxian Wang et al.
GENES CHROMOSOMES & CANCER (2022)
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics
Yoshikatsu Kanai
PHARMACOLOGY & THERAPEUTICS (2022)
Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple-negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways
Shan Zhu et al.
CANCER CELL INTERNATIONAL (2021)
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer
Arafath K. Najumudeen et al.
NATURE GENETICS (2021)
Inhibition of glioma by adenovirus KGHV500 encoding anti-p21Ras scFv and carried by cytokine-induced killer cells
Jing Qian et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2021)
RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480
Chen-Chen Huang et al.
BMC CANCER (2021)
Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment
Marianna Nachef et al.
FRONTIERS IN IMMUNOLOGY (2021)
Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
Veronica Aran et al.
MEDICINA-LITHUANIA (2021)
Cytokine-induced killer cells carrying recombinant oncolytic adenovirus expressing p21Ras scFv inhibited liver cancer
Fang Dai et al.
JOURNAL OF CANCER (2021)
Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer
Rokaya El Ansari et al.
BRITISH JOURNAL OF CANCER (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Targeting Krasg12c-mutant cancer with a mutation-specific inhibitor
J. G. Christensen et al.
JOURNAL OF INTERNAL MEDICINE (2020)
ZNF24 is upregulated in prostate cancer and facilitates the epithelial-to-mesenchymal transition through the regulation of Twist1
Xiangjiang Huang et al.
ONCOLOGY LETTERS (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
linc00174-EZH2-ZNF24/Runx1-VEGFA Regulatory Mechanism Modulates Post-burn Wound Healing
Mitao Huang et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Review of the Correlation of LAT1 With Diseases: Mechanism and Treatment
Jingshun Zhang et al.
FRONTIERS IN CHEMISTRY (2020)
The Function of RAS Mutation in Cancer and Advances in its Drug Research
Shijie Chen et al.
CURRENT PHARMACEUTICAL DESIGN (2019)
Isoprenylcysteine carboxylmethyltransferase is associated with nasopharyngeal carcinoma chemoresistance and Ras activation
Yongbo Zhu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression
Kentaro Inamura
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Irene Ferrer et al.
LUNG CANCER (2018)
The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health
Mariafrancesca Scalise et al.
FRONTIERS IN CHEMISTRY (2018)
Therapeutic strategies to target RAS-mutant cancers
Meagan B. Ryan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications
Biagio Ricciuti et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2016)
miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway
Marijn T. M. van Jaarsveld et al.
MOLECULAR CANCER (2015)
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Frederick D. Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
MicroRNA-940 promotes tumor cell invasion and metastasis by downregulating ZNF24 in gastric cancer
Xinyang Liu et al.
ONCOTARGET (2015)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma
Kyoichi Kaira et al.
PATHOLOGY & ONCOLOGY RESEARCH (2013)
Zinc finger transcription factor 191, directly binding to β-catenin promoter, promotes cell proliferation of hepatocellular carcinoma
Guoyuan Liu et al.
HEPATOLOGY (2012)
Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression
Qian Wang et al.
CANCER RESEARCH (2011)
Inhibition of Ras for cancer treatment: the search continues
Antonio T. Baines et al.
FUTURE MEDICINAL CHEMISTRY (2011)
KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
S. Kamel-Reid et al.
Current Oncology (2010)
Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies
Lihua Cheng et al.
GYNECOLOGIC ONCOLOGY (2010)
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
Bret B. Friday et al.
CLINICAL CANCER RESEARCH (2008)
The zinc finger transcription factor 191 is required for early embryonic development and cell proliferation
Jianzhong Li et al.
EXPERIMENTAL CELL RESEARCH (2006)
Share Paper
